Ohar JA - Search Results

1

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.

Ohar JA, Crater GD, Emmett A, Ferro TJ, Morris AN, Raphiou I, Sriram PS, Dransfield MT. Ohar JA, et al. Respir Res. 2014 Sep 24;15(1):105. doi: 10.1186/s12931-014-0105-2. Respir Res. 2014. PMID: 25248764 Free PMC article. Clinical Trial.

2

Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers.

Sadeghnejad A, Ohar JA, Zheng SL, Sterling DA, Hawkins GA, Meyers DA, Bleecker ER. Sadeghnejad A, et al. Among authors: ohar ja. Respir Res. 2009 Mar 12;10(1):21. doi: 10.1186/1465-9921-10-21. Respir Res. 2009. PMID: 19284602 Free PMC article.

3

Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.

Ohar JA, Donohue JF. Ohar JA, et al. Semin Respir Crit Care Med. 2010 Jun;31(3):321-33. doi: 10.1055/s-0030-1254072. Epub 2010 May 21. Semin Respir Crit Care Med. 2010. PMID: 20496301 Review.

4

Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?

Miles MC, Donohue JF, Ohar JA. Miles MC, et al. Among authors: ohar ja. Drugs. 2012 Feb 12;72(3):301-8. doi: 10.2165/11598580-000000000-00000. Drugs. 2012. PMID: 22316346 Review.

5

Nebulized arformoterol: what is its place in the management of COPD?

Miles MC, Donohue JF, Ohar JA. Miles MC, et al. Among authors: ohar ja. Ther Adv Respir Dis. 2013 Apr;7(2):81-6. doi: 10.1177/1753465812465784. Epub 2012 Nov 12. Ther Adv Respir Dis. 2013. PMID: 23147985 Free article. Review.

6

Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.

Loh CH, Donohue JF, Ohar JA. Loh CH, et al. Among authors: ohar ja. Expert Opin Drug Saf. 2015 Mar;14(3):463-72. doi: 10.1517/14740338.2015.998196. Epub 2015 Jan 7. Expert Opin Drug Saf. 2015. PMID: 25563342 Review.

7

Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.

Davidson JF, Donohue JF, Ohar JA. Davidson JF, et al. Among authors: ohar ja. Expert Opin Drug Saf. 2015 Feb;14(2):317-24. doi: 10.1517/14740338.2015.983898. Expert Opin Drug Saf. 2015. PMID: 25598422 Review.

8

Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease.

Liu Y, Pleasants RA, Croft JB, Lugogo N, Ohar J, Heidari K, Strange C, Wheaton AG, Mannino DM, Kraft M. Liu Y, et al. Respir Med. 2015 Jul;109(7):851-9. doi: 10.1016/j.rmed.2015.05.006. Epub 2015 May 16. Respir Med. 2015. PMID: 26006753 Free PMC article.

9

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA.

Cohen JS, Miles MC, Donohue JF, Ohar JA. Cohen JS, et al. Among authors: ohar ja. Int J Chron Obstruct Pulmon Dis. 2016 Apr 15;11:785-97. doi: 10.2147/COPD.S54513. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27143870 Free PMC article. Review.

10

Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions.

Loh CH, Peters SP, Lovings TM, Ohar JA. Loh CH, et al. Among authors: ohar ja. Ann Am Thorac Soc. 2017 Aug;14(8):1305-1311. doi: 10.1513/AnnalsATS.201611-903OC. Ann Am Thorac Soc. 2017. PMID: 28406710

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters